www.youtube.com/watch?v=OhkwfZWM5TQ

Read the original here:
Wind River Optimizes its Intelligent Systems for 3rd Generation Intel® Core™ Processors – Video

aap Implantate AG, a medical technology company listed in the Frankfurt Stock Exchange`s Prime Standard segment, generated EUR9.9 million in sales (previous year: EUR6.5 million) in the first three months of financial year 2012, which was a 51% increase on the previous year`s first quarter. This strong sales growth was due mainly to an 18% increase in product sales to EUR7.7 million (previous year: EUR6.5 million) and to revenue from the conclusion of an exclusive license agreement worth EUR2.2 million with a world-leading medical technology company. EBITDA increased to EUR2.1million (previous year: EUR0.8 million).

*Full-Time-Equivalents (FTE) are the number of full-time employed persons during a period

In the first quarter of 2012 aap Group`s EBIT was EUR1.3million (previous year: EUR0.1 million) and its EBT amounted to EUR1.2 million (previous year: EUR0.1 million). On a balance sheet total of EUR67.1 million (31.12.2011: EUR63.4 million) the equity ratio was 74%.

In the first quarter, aap presented its innovative LOQTEQ product line to potential new distributors in Europe, the United States, Asia and Latin America, while the centre of excellence for trauma in Berlin continued to work on the FDA approval of the LOQTEQ product family. aap expects to receive full FDA approval on the LOQTEQ product line in the third quarter of 2012. The center of excellence for contract manufacturing in Nijmegen signed in the first quarter a contract to process human tissue with the Dutch Sanquin bone and tissue bank.

Outlook for 2012

On the basis of the positive result for the first quarter, the current order intake and potential new customer relationships, aap Implantate AG is revising its sales forecast for the financial year 2012. The Management Board now anticipates total sales of around EUR34 million (previous forecast: aroundEUR 32 million), or 16% sales growth on the previous year.

The main strategic focus in the financial year 2012 will be on the core business segments trauma and bone cement and cementing techniques, in which aap aims to achieve double-digit sales growth and a positive Cash-EBIT. Sales growth is to be realised through the launch of the innovative LOQTEQ product line and its FDA approval along with further strong sales growth in the bone cement and cementing techniques segment, license business, OEM contracts and another project deal.

aap Implantate AG`s full report for the first quarter of 2012 is available for you to download at www.aap.de.

This release contains forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap`s public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments. ______________________________________________________ aap Implantate AG (ISIN DE0005066609) – Prime Standard/Regulated Market – All German stock markets –

aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company`s products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company`s products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap`s stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de.

View post:
aap reports profitable Q1 2012 sales growth of 51% to EUR 9.9 million; Increased sales forecast for the financial year …

Breakthrough by Irish scientists could spell end of needle jab

By Eoin English

Tuesday, May 15, 2012

Scientists based at an Irish research hub are developing medical technology which could spell the end of the dreaded needle jab.

Almost 180 clinicians, scientists and entrepreneurs from 25 countries are in Cork this week to discuss the future of microneedle technology at a conference hosted by the Tyndall National Institute and UCC.

Microneedles, which consist of tiny spikes just 0.1mm to 1.0mm in length, are made using techniques adapted from the computer chip industry.

Arrays of microneedles will be worn like a plaster or skin patch, where they will penetrate the skin and release a drug or vaccine into the body.

They will be used to treat conditions ranging from diabetes to osteoporosis, and will play a major role in low-cost public health management activities such as the annual flu vaccination programme.

But crucially, because they are microscopic, they are completely painless to wear, and users will no longer need to attend a doctors surgery for needle-based injections.

Experts reckon the devices will be on the market within just a few years, capturing a slice of a $30bn (23.36bn) medical market.

Visit link:
Breakthrough by Irish scientists could spell end of needle jab

RICHLAND, Wash.–(BUSINESS WIRE)–

IsoRay Inc. (AMEX: ISR – News), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced its financial results for the third fiscal quarter ended March 31, 2012.

IsoRay Chairman and CEO Dwight Babcock commented, “Our quarterly financial performance, while flat, reflects the building of inventory and marketing efforts aimed at growing product awareness in anticipation of the launch of our GliaSite radiation therapy system and lung cancer mesh sales internationally. Our revenues from sales for the treatment of other body sites beyond the prostate grew 27% comparing the nine months ended March 31, 2012 to the nine months ended March 31, 2011. We also saw growth in the number of physicians and facilities ordering cases for non-prostate body sites. The number of physicians ordering grew 57% and the number of facilities ordering grew 60% year to date respectively.”

The GliaSite radiation therapy system is the world’s only balloon catheter device used in the treatment of brain cancer, and is being reintroduced to the market by IsoRay, which has exclusive worldwide rights to the system. IsoRay is also the exclusive manufacturer of Cesium-131, which represents one of the most important advancements in internal radiation therapy in 20 years. Cesium-131 allows for the internal radiation treatment of many different cancers because of its peerless combination of high energy and its matchless speed in giving off therapeutic radiation (9.7 day half-life).

IsoRay has taken some significant steps forward during the quarter. A growing number of institutions, including John Hopkins Hospital, Columbia University Medical Center, Baylor and others, are seeking amendments to their state radiation licenses. Typically, a license amendment is a 2 to 4 month process which allows institutions, upon approval, to make IsoRay’s products available for patient treatment.

In recent weeks, the Company participated in the 80th Annual Meeting of the American Association of Neurological Surgeons (AANS) marking the Company’s formal introduction to the neuroscience community. During the meeting, a number of thought leaders in the medical community spoke about their experiences with the GliaSite radiation therapy system. At the meeting, one physician reported historical results with GliaSite in treating his last surviving patient with metastasized brain cancer. This metastasized brain cancer patient experienced an extraordinary 6 year extension of life with improved quality of life.

IsoRay also participated in the World Congress of Brachytherapy in Barcelona, Spain where the Company reintroduced the GliaSite brain cancer treatment and introduced its Cesium-131 lung cancer mesh to the international community. At the meeting, the Company met with 10 international distributors from a variety of countries who are seeking international distribution agreements for IsoRay’s products. IsoRay CEO Babcock says the Company is currently engaged in due diligence to evaluate whether to proceed with negotiations with those companies.

Also at that meeting, a number of studies, as published in the Brachytherapy Journal of the ABS, were presented spotlighting crucial findings regarding Cesium-131 brachytherapy. New York Presbyterian Radiation Oncologist Dr. A. Gabriella Wernicke, M.D., M.Sc., presented a paper reporting on the successful results New York-Presbyterian/Weill Cornell Medical Center doctors have achieved using sutured Cesium-131 seeds to treat metastasized brain cancer. Dr. Bhupesh Parashar, Radiation Oncologist at New York-Presbyterian/Weill Cornell Medical Center, presented an initial report of outcomes relative to toxicity and radiation exposure in the use of Cesium-131 brachytherapy for head and neck cancers. The report concludes that Cesium-131 brachytherapy is a safe and effective option for high risk head and neck cancers, producing high control rates, limited toxicity and is safe for health personnel in terms of radiation exposure. In addition, UPMC radiation oncologist and associate professor of radiation oncology Dr. Sushil Beriwal reported on long term toxicity following Cs-131 prostate brachytherapy. Dr. Beriwal and his colleagues found most patients undergoing prostate brachytherapy with Cs-131 have no urinary or bowel toxicity at the three year post-brachytherapy mark. Dr. Beriwal also presented a paper which investigated whether there is a difference in PSA spikes using Cesium-131 brachytherapy as opposed to other radioisotopes. While Cesium-131 treats cancer more aggressively, the report states that it has no different long term PSA spike effect than other radioisotopes. In addition, Dr. Deepak Khuntia, Director of Research and Education for Western Radiology Oncology in California, was a speaker on Robot Assisted Mesh Brachytherapy after Sublobar Resection for Early Stage Lung Cancer. In comments following his presentation, Dr. Khuntia cited several advantages in the use of Cesium-131 in robot assisted mesh brachytherapy treatment over radioisotope I-125.

Net loss applicable to common shareholders

Weighted average shares used in computing net loss per share:

See the article here:
IsoRay, Inc. Reports Third Quarter Results

Continued here:
St Jude is latest to launch blood pressure device

CHARLOTTE, N.C.–(BUSINESS WIRE)–

Camstar Systems, Inc. announced today an agreement to deploy its Camstar Enterprise Platform for medical device manufacturer Stryker, a leading medical technology company that helps healthcare professionals perform their jobs more efficiently while enhancing patient care.

Stryker is dedicated to offering top quality products and services that provide enduring value to medical professionals and patients, said Brian Rieck, program director, IT integration for Stryker. The Camstar solution gives us great control over our manufacturing processes and allows us to streamline and lock down critical steps to ensure the process works as intended, every time.

Stryker joins other leading global manufacturers that place the highest importance on patient safety and understand the strategic value of standardizing on Camstars Enterprise Platform, said Rob Rudder, executive vice president for Camstar. Camstars clear leadership and investment in the medical device manufacturing industry are making a difference to this important industry.

About Stryker

Stryker is one of the worlds leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care. The Company offers a diverse array of innovative medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products to help people lead more active and more satisfying lives.

For more information, please visit www.stryker.com.

About Camstar Systems, Inc.

Camstar is a leading innovator of software solutions that advance product quality in the manufacturing industry, enabling Brand Owners, Manufacturers and Suppliers to produce the highest quality products through Global Supply Networks. Camstars cloud-based and on-premise solutions provide Supply Chain Visibility and Intelligence, Quality Management and Collaboration, and Manufacturing Execution.

For nearly 30 years, Camstar has servedhundreds of satisfied customers worldwide. For more information, please visit www.camstar.com.

Follow this link:
Stryker Deploys Camstar to Enable Growth, Efficiency and Top Product Quality

Published on May 16, 2012 at 2:16 AM

HyperBranch Medical Technology, Inc. announced today that it has received CE Marking for AdherusTM AutoSpray Dural Sealant. Adherus AutoSpray is a novel delivery system used for the delivery of HyperBranch’s dural sealant which is used in cranial and spine surgeries to prevent cerebrospinal fluid leaks following the dural repair. Prevention of cerebrospinal fluid leaks should benefit the patient in fewer post-surgical complications such as leaks and infection thereby resulting in shorter hospital stays. The CE Mark provides regulatory approval for the company to begin sales in countries outside the U.S.

“Adherus AutoSpray is the first self-contained bioadhesive spray applicator that eliminates cumbersome preparation steps for the scrub nurse and allows the surgeon to effortlessly and precisely start and stop dispensing without concern for clogging. It complements the Company’s other neurosurgery products: AdherusTM Dural Sealant and AdherusTM MIS. All the Company’s products share the same proprietary chemistry that provides controlled performance while degrading slowly during the healing process. It not only provides a watertight seal but acts as an adhesion barrier to limit scarring, a major advantage if subsequent surgery is required,” said John Conn, President and Chief Executive Officer.

The AdherusTM products are synthetic hydrogels which polymerize in a moist field, flow optimally depending on the application, and biodegrade as the tissue heals.

HyperBranch Medical Technology, Inc. has now received CE Marks for five of their products. The Company has completed a U.S. feasibility study and is nearing completion of the Pivotal portion for its cranial product which includes the new AutoSpray device. An FDA IDE for the MIS device has also been approved and will follow the same approval path in the U.S. as the AutoSpray.

Source: HyperBranch Medical Technology

View post:
HyperBranch’s Adherus AutoSpray Dural Sealant receives CE Marking

DURHAM, N.C.–(BUSINESS WIRE)–

HyperBranch Medical Technology, Inc. announced today that it has received CE Marking for AdherusTM AutoSpray Dural Sealant. Adherus AutoSpray is a novel delivery system used for the delivery of HyperBranchs dural sealant which is used in cranial and spine surgeries to prevent cerebrospinal fluid leaks following the dural repair. Prevention of cerebrospinal fluid leaks should benefit the patient in fewer post-surgical complications such as leaks and infection thereby resulting in shorter hospital stays. The CE Mark provides regulatory approval for the company to begin sales in countries outside the U.S.

“Adherus AutoSpray is the first self-contained bioadhesive spray applicator that eliminates cumbersome preparation steps for the scrub nurse and allows the surgeon to effortlessly and precisely start and stop dispensing without concern for clogging. It complements the Companys other neurosurgery products: AdherusTM Dural Sealant and AdherusTM MIS. All the Companys products share the same proprietary chemistry that provides controlled performance while degrading slowly during the healing process. It not only provides a watertight seal but acts as an adhesion barrier to limit scarring, a major advantage if subsequent surgery is required, said John Conn, President and Chief Executive Officer.

The AdherusTM products are synthetic hydrogels which polymerize in a moist field, flow optimally depending on the application, and biodegrade as the tissue heals.

HyperBranch Medical Technology, Inc. has now received CE Marks for five of their products. The Company has completed a U.S. feasibility study and is nearing completion of the Pivotal portion for its cranial product which includes the new AutoSpray device. An FDA IDE for the MIS device has also been approved and will follow the same approval path in the U.S. as the AutoSpray.

HyperBranch Medical Technology is a privately-held company based in Durham, N.C. The company is focused on the development of unique products based on its novel hydrogel technology. Development work on HyperBranchs surgical sealant platform has led to the recognition of several novel hydrogel properties that suggest significant utility in a variety of clinical applications. For more information, visit www.hyperbranch.com.

Read this article:
HyperBranch Receives Approval for Adherus AutoSpray Dural Sealant

WESTBURY, N.Y.–(BUSINESS WIRE)–

Vasomedical, Inc. (Vasomedical) (OTC: VASO.PK), a diversified medical technology company specializing in the design, manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products, today reported its operating results for the three months ended March 31, 2012.

The Company recorded revenue of $6.04 million for the three month period ended March 31, 2012, compared to revenue of $4.85 million for same period in 2011, an increase of 25%. The increase is primarily due to an increase of $925,000 in EECP and other medical equipment sales, or 175%, of which $578,000 was contributed by our recent acquisitions in China. Commission revenue at our wholly-owned subsidiary Vaso Diagnostics, Inc., d/b/a VasoHealthcare, also grew by $317,000, or 8%, for the three month period ended March 31, 2012. We continue to record substantial amounts of deferred revenues, which will be recognized once the underlying equipment or service is accepted or performed. As of March 31, 2012, total deferred revenues were approximately $14.78 million, a decrease of $0.45 million from December 31, 2011. At March 31, 2012, the Company had cash and cash equivalents of approximately $13.3 million.

Net loss for the three months ended March 31, 2012 was $1.34 million, compared to a net loss of $0.47 million for the same period in 2011. The increase in net loss was due to higher selling, general and administrative costs associated mainly with additional sales and marketing investments at our Vaso Diagnostics subsidiary, the addition of the China operations, and increased corporate expenses. Loss attributable to common stockholders was $1.34 million or $0.01 per common share for the three months ended March 31, 2012, compared to a net loss of $0.59 million or $0.01 per common share for the three months ended March 31, 2011.

We are excited about the revenue growth in both segments but especially with the growth in our equipment segment, commented Dr. Jun Ma, President and Chief Executive Officer of the Company. We anticipate that our equipment segment will continue to grow and contribute significantly to our future success, Dr. Ma continued. We will continue to seek other opportunities to expand our equipment segment to further diversify our business and to enhance shareholder value.

About Vasomedical

Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company operates through three wholly-owned subsidiaries. Vasomedical Solutions manages and coordinates the design, manufacture and sales of EECP therapy systems, its core product, as well as other medical equipment operations; Vasomedical Global operates the Companys China-based subsidiaries; and Vaso Diagnostics, d/b/a VasoHealthcare, is the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products. Additional information is available on the Company’s website at www.vasomedical.com.

Summarized Financial Information

STATEMENTS OF OPERATIONS

BALANCE SHEETS

Read the original post:
Vasomedical Announces Strong Revenue Growth for the Three Months Ended March 31, 2012

PRINCETON, N.J. & PARIS–(BUSINESS WIRE)–

STENTYS S.A. (STNT.PA), a medical technology company commercializing the world’s first and only Self-Apposing Stent to treat Acute Myocardial Infarction (AMI), announced today that it is launching a thrombectomy device (aspiration catheter) called STENTYS AC.

Heart attacks are caused by the occlusion of a coronary artery due to clot formation. The European Society of Cardiology (ESC) recommends that cardiologists try removing as much clot chunks as possible prior to implanting a stent in order to minimize distal embolization (blockage of downstream vessels). STENTYS AC is designed to safely recover debris and can be used in concert with its Self-Apposing devices, STENTYS BMS and STENTYS DES.

Coronary thrombectomy devices are a $40 million market and we are very pleased to offer our customers a device with the best aspiration power on the market to be used with our breakthrough Self-Apposing Stents for treating AMI, said Gonzague Issenmann, CEO of STENTYS. STENTYS is building a portfolio to offer the complete AMI solution to the cath lab

About STENTYS

Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI) and bifurcation lesions. Founded by Jacques Sguin, M.D., Ph.D. and Gonzague Issenmann, STENTYS received CE-marking for its flagship products in 2010. Its Self-Apposing stent adapts to the anatomic changes of arteries in the post-infarction phase and thus prevents the malapposition problem associated with conventional stents. STENTYS has commenced marketing activities in several European countries.

This announcement is not an offer for sale of securities in the United States. The securities referred to herein have not been offered or sold in the United States and may not be offered or sold in the United States of America, except pursuant to a registration statement under theU.S. Securities Act of 1933, as amended(the “Securities Act”),or pursuant to an exemption from registrations thereunder. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.

Read the original post:
STENTYS Expands Its Product Offerings for Treating Heart Attacks

PLEASANTON, Calif., May 14, 2012 (GLOBE NEWSWIRE) — ZELTIQ Aesthetics, Inc. (Nasdaq:ZLTQ – News), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, together with the Massachusetts General Hospital (MGH), announced that the Mercantile Court in Spain on May 4 ruled in their favor regarding the patent infringement lawsuit jointly filed in Spain against Clinipro and Aquaestetica, its Spanish distributor.

The lawsuit against Clinipro alleged infringement of two European patents owned by MGH and licensed exclusively to ZELTIQ. After hearing the petition, the Mercantile Court in Spain granted ZELTIQ’s and MGH’s request for a preliminary injunction against further importation, distribution and sales of Clinipro’s LipoCryo device in Spain. Furthermore, the court order allows for the removal and seizure of all of Clinipro’s LipoCryo systems in Spain.

Mark Foley, interim President and Chief Executive Officer of ZELTIQ, commented, “We are very pleased to announce this ruling. Our clear victory reinforces both the strength of our intellectual property rights and our efforts to defend these rights on a global basis. This is our second legal win internationally defending our IP in the past two months. We will immediately have these infringing systems removed from the market per the court’s ruling. As we previously announced, we also have a lawsuit underway against Clinipro in France and we are optimistic for an equally favorable outcome.”

Separately, the Company announced that it has secured removal and undertakings regarding three separate web site infringement matters against Beijing Smart Light, Joyful Tech Group, and Create Beauty Technology Group. In each case, the infringing companies have agreed to remove all content and materials from their web sites that violate ZELTIQ’s intellectual property. ZELTIQ will continue to monitor these entities and others to protect and enforce its IP rights in China.

About ZELTIQ Aesthetics

ZELTIQ Aesthetics is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. The Company’s first commercial product, the CoolSculpting System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis, without causing scar tissue or damage to the skin, nerves, or surrounding tissues. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.

More:
ZELTIQ Aesthetics Granted Preliminary Injunction in Infringement Case Against Clinipro in Spain

Call for Repeal of Medical Device Tax

COLUMBUS, Ohio, May 14, 2012 /PRNewswire-USNewswire/ — Top leaders representing America’s advanced medical technology and diagnostics industry came together today to discuss pressing public policy issues affecting job creation and medical innovation and to call for the repeal of the more than $20 billion medical device tax set to begin in January 2013.

U.S. Reps. Patrick J. Tiberi (R-Ohio) and Jim Renacci (R-Ohio) joined Walter M Rosebrough, president and CEO of Mentor, Ohio-based STERIS, and Mike Lynch, executive vice president of Dublin, Ohio-based Cardinal Health, along with Advanced Medical Technology Association (AdvaMed) President and CEO Stephen J. Ubl and BioOhio CEO Tony Dennis, in the policy discussion.

The group had a simple message: The medical technology industry is not only critical to quality health care, but to the creation of innovative new jobs in Ohio and across the country.

Medical technology companies in Ohio and across the country are world leaders in the development of new medical devices, diagnostics and essential equipment for patients worldwide, but that leadership is at risk.

“Our industry can be a partner in job creation and an engine for growth for our national economic recovery but public policies need to support that growth and allow us to compete on the global stage. Repealing the device tax is an important first step,” Ubl said.

Medical technology is one of the only American manufacturing sectors that has a net trade surplus, exporting $5.4 billion more than it imports. It also accounts for 40 percent of the global technology market. But the U.S.’s lead has shrunk dramatically in the last decade, and we stand to lose further ground with the new tax.

To preserve and protect those jobs and the life-changing innovations created locally, AdvaMed and its member companies have developed a comprehensive Competitiveness Agenda. The agenda focuses on innovation, regulatory, reimbursement, tax and trade policies to drive the U.S. medical technology industry’s future growth and success. A copy of the agenda can be found here: http://advamed.org/MemberPortal/Issues/CompetitivenessAgenda.

Originally posted here:
AdvaMed & BioOhio Discuss MedTech Impact on Ohio's Economy, Job Creation

CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–

CardioNet, Inc. (NASDAQ:BEAT – News), a leading wireless medical technology company with an initial focus on the diagnosis and monitoring of cardiac arrhythmias, announced today that Anthony J. Conti has joined the CardioNet Board of Directors and will serve as the Chairman of its Audit Committee. Mr. Conti is an esteemed leader whose illustrious career includes 37 years with PricewaterhouseCoopers before his retirement in 2009. Mr. Conti replaces Kirk Gorman, who will continue to serve as the Companys Chairman of the Board.

I am extremely pleased to announce the appointment of Anthony J. Conti to the CardioNet Board of Directors, noted Joseph H. Capper, CEO of CardioNet, Inc. Mr. Contis superior leadership and financial expertise will serve as valuable assets to the CardioNet Board. We look forward to his contribution as we continue to execute on our strategic initiatives.

Mr. Conti joined Coopers and Lybrand in 1973, and served a wide range of industrial, technology, utility and health services clients. Mr. Conti held a number of leadership roles with Coopers and Lybrand, and later with PricewaterhouseCoopers, after its merger with Price Waterhouse in 1998. He presently serves as the Chairman of the Audit Committee for Ametek, Inc., an electronic instrument and electromechanical device company.

Mr. Contis professional merits are complemented by his strong commitment to serving his community. Mr. Conti served as Chairman of the Board of the World Affairs Council of Philadelphia until December of 2011, and now serves as Chairman Emeritus. He also served as a Member of the Board and Executive Committee of the United Way of Southeastern Pennsylvania.

Mr. Conti holds a Bachelors of Arts degree in Economics from St. Joseph’s University and a Masters of Business Administration from Temple University.

About CardioNet

CardioNet is the leading provider of ambulatory, continuous, real-time outpatient management solutions for monitoring relevant and timely clinical information regarding an individual’s health. CardioNet’s initial efforts are focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, with a solution that it markets as Mobile Cardiac Outpatient Telemetry (MCOT). More information can be found at http://www.cardionet.com.

Forward-Looking Statements

This document includes certain forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our growth prospects, the prospects for our products and our confidence in the Companys future. These statements may be identified by words such as expect, may, anticipate, possible, estimate, potential, intend, plan, believe, forecast, promises and other words and terms of similar meaning. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of them, and could cause actual outcomes and results to differ materially from current expectations. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including our latest periodic reports on Form 10-K and 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

More:
CardioNet, Inc. Appoints Anthony J. Conti to Its Board of Directors

www.youtube.com/watch?v=QWBerNQY2LU

More:
Extreme Affordability: Innovative Solutions for Surgical Care, Joel Ehrenkranz, MD – Video

Read more:
Covidien Teams Up with GE Health – Analyst Blog

Philadelphia, PA (PRWEB) May 12, 2012

An extremely low cost medical equipment heater technology is to be announced and displayed at MD&M East, the Medical Design & Manufacturing Trade Show in Philadelphia, May 22-24, by Heatron, Inc. View the new technology at Heatron’s booth, Booth 2444.

Heatron, Inc., a manufacturer of custom heating elements for medical equipment will be displaying a new technology, a very low cost (throw-away cost) heating element that could potentially either create a new market in medical products that need heat applied, or even to lower the cost of some medical equipment.

Specialized heating elements used in medical products have always been somewhat expensive, however, Heatron has developed a totally new heating element technology that is not only flexible and submersible, but can be incorporated in some rather unique approaches right on down to bandages, tape, and other low cost and disposable medical products.

This new technology is a major breakthrough for medical applications that require some heat for healing. One application is in advanced wound care healing where heat can increase the rate of healing. Wound healing is one area of healthcare and medical equipment that could benefit from a throw-way heating element.

Heatron manufacturers heating elements for medical equipment such as blood warmers for open heart surgery, hemodialysis machines, breathalyzers, chemical analyzers, fluid warmers for hypodermic injections, etc

More:
MD&M East — Heatron to Release New Low Cost Medical Heater Technology

BERLIN–(Marketwire -05/11/12)- BIOTRONIK, a leading manufacturer of innovative medical technology, announced today that the first ICD implantation has been performed on a patient enrolled in the BIOTRONIK ESCAPE-ICD Registry in Latin America.

ESCAPE-ICD is a large-scale observational study sponsored by BIOTRONIK and designed to tackle the alarming lack of data on sudden cardiac death in Latin America.

“The aim of the ESCAPE-ICD registry is to evaluate the size of the Latin American population at risk of sudden cardiac death and to collect clinical evidence so that we can provide primary prevention information to physicians,” said Dr. William Uribe, Principal Investigator of the Study.

Despite sudden cardiac death being a major cause of death world-wide(1), there is little epidemiological data about its prevalence in the countries involved in the registry: Argentina, Brazil, Colombia, Chile, Mexico and Venezuela.

The massive scale and scope of this undertaking has been defined in line with BIOTRONIK’s ambition to lead the industry in clinical excellence by providing answers in the most important areas of cardiovascular research and thereby optimizing therapies for cardiovascular patients.

“We are delighted to be taking part in the ESCAPE-ICD registry and to have performed the first ICD implantation on a patient who was at risk of sudden cardiac death. This registry has been long-awaited and we anticipate that we will be able to gather more data to help us address and prevent the problem of sudden death in our patients,” said Dr. Luis E. Aguinaga, Clinical Cardiac Electrophysiologist at Private Center of Cardiology (Centro Privado de Cardiologa) in Tucumn, Argentina.

The study consists of two stages: the first will include 12,500 patients in order to evaluate the prevalence of patients at risk and the second stage will be used to compare patients who are only taking medical treatment with patients who have had an ICD implanted.

Dr. Sergio J. Dubner, Principal Investigator of the Study, commented, “Primary prevention of sudden cardiac death is a subject that is long overdue to come to the forefront in Latin America. It’s a great scientific challenge to identify patients at high risk of sudden cardiac death and analyze their incidence, their geographical distribution, and existing differences with other areas in the world. BIOTRONIK’s ESCAPE ICD registry will help provide physicians in Latin America the necessary data to identify patients and provide the best possible treatment.”

ESCAPE-ICD Steering Committee

Reference(1) World Health Organization fact sheet No 317, www.who.int

Continued here:
First ICD Implantation Performed on Patient in BIOTRONIK's ESCAPE-ICD Registry in Latin America